A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC

Inclusion Criteria: * Histologically or cytologically documented Stage IV NSCLC not amenable to curative surgery or radiation * No prior chemotherapy or any other systemic therapy for metastatic NSCLC * Prior platinum-containing adjuvant, neoadjuvant, or definitive chemoradiation for advanced disease are eligible, if progression has occurred \>12 months from end of last therapy * Known tumor PD-L1 status * Tumors that lack activating EGFR mutations and ALK fusions or documented local test result for any other known genomic alteration for which a targeted therapy is approved in first line per local standard of care * WHO/ECOG status at 0 or 1 at enrollment * Life expectancy of at least 12 weeks * Troponin I or T ≤ ULN (per institutional guidelines) Exclusion Criteria: * Active or prior documented autoimmune or inflammatory disorders * History of active primary immunodeficiency * Any prior chemotherapy or any other systemic therapy for metastatic NSCLC * Untreated CNS metastases